

Lung Cancer Therapeutics Market - 2023-2033

<https://marketpublishers.com/r/L00859AAFED7EN.html>

Date: January 2026

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: L00859AAFED7EN

Abstracts

The Lung Cancer Therapeutics Market was valued at US\$ 24.00 Billion in 2023 and is anticipated to reach US\$ 55.09 Billion by 2033, at a CAGR of 0.088 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Lung Cancer Therapeutics Market.

This report delivers a comprehensive overview of the Lung Cancer Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Lung Cancer Therapeutics Market. The Lung Cancer Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.

Lung Cancer Therapeutics Market Scope:

Key Players

Key Players

Pfizer

Merck & Co

Amgen Inc.

AstraZeneca

Boehringer Ingelheim

Bristol-Myers Squibb Company

Novartis AG

Eli Lilly and Company

Hoffmann-La Roche

AbbVie, Inc

Major Highlights

This report delivers a comprehensive overview of the Lung Cancer Therapeutics Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Lung Cancer Therapeutics Market. The Lung Cancer Therapeutics Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2023–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the

latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

1. MARKET INTRODUCTION AND SCOPE

- 1.1. Objectives of the Report
- 1.2. Report Coverage & Definitions
- 1.3. Report Scope

2. EXECUTIVE INSIGHTS AND KEY TAKEAWAYS

- 2.1. Market Highlights and Strategic Takeaways
- 2.2. Key Trends and Future Projections
- 2.3. Snippet by Type
- 2.4. Snippet by Treatment Type
- 2.5. Snippet by Route of Administration
- 2.6. Snippet by Distribution Channel
- 2.7. Snippet by Region

3. DYNAMICS

- 3.1. Impacting Factors
 - 3.1.1. Drivers
 - 3.1.1.1. Rising Global Incidence of Lung Cancer
 - 3.1.1.2. Advancements in Immunotherapy and Targeted Therapies
 - 3.1.1.3. Government & Private Sector Support for Early Screening and Diagnostics
 - 3.1.2. Restraints
 - 3.1.2.1. High Cost of Advanced Therapies
 - 3.1.2.2. Limited Access to Diagnostic Infrastructure in Emerging Markets
 - 3.1.2.3. Drug Resistance and Tumor Heterogeneity
 - 3.1.3. Opportunity
 - 3.1.3.1. Growth in Early Detection Tools & Liquid Biopsy Technologies
 - 3.1.3.2. Development of Biosimilars and Cost-Effective Therapies
 - 3.1.4. Impact Analysis

4. GLOBAL LUNG CANCER THERAPEUTICS MARKET: STRATEGIC INSIGHTS AND INDUSTRY OUTLOOK

- 4.1. Market Leaders and Pioneers
 - 4.1.1. Emerging Pioneers and Prominent Players

- 4.1.2. Established leaders with largest largest-selling Brand
- 4.1.3. Market leaders with established products & Services
- 4.2. Latest Developments and Breakthroughs
- 4.3. Regulatory and Reimbursement Landscape
 - 4.3.1. North America
 - 4.3.2. Europe
 - 4.3.3. Asia Pacific
 - 4.3.4. South America
 - 4.3.5. Middle East & Africa
- 4.4. Porter's Five Force Analysis
- 4.5. Supply Chain Analysis
- 4.6. Patent Analysis
- 4.7. SWOT Analysis
- 4.8. Unmet Needs and Gaps
- 4.9. Recommended Strategies for Market Entry and Expansion
- 4.10. Pricing Analysis and Price Dynamics

5. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY TYPE

- 5.1. Introduction
 - 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
 - 5.1.2. Market Attractiveness Index, By Type
- 5.2. Non-Small Cell Lung Cancer (NSCLC)*
 - 5.2.1. Introduction
 - 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 5.3. Small Cell Lung Cancer (SCLC)

6. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY TREATMENT TYPE

- 6.1. Introduction
 - 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
 - 6.1.2. Market Attractiveness Index, By Treatment Type
- 6.2. Chemotherapy*
 - 6.2.1. Introduction
 - 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
 - 6.2.3. Paclitaxel (Taxol)
 - 6.2.4. Albumin-bound paclitaxel (nab-paclitaxel, Abraxane)
 - 6.2.5. Docetaxel (Taxotere)
 - 6.2.6. Gemcitabine (Gemzar)

- 6.2.7. Others
- 6.3. Radiation Therapy
 - 6.3.1. External Beam
 - 6.3.2. Internal Beam
 - 6.3.3. Proton Therapy
- 6.4. Targeted Therapy
 - 6.4.1. Angiogenesis inhibitors
 - 6.4.2. KRAS inhibitors
 - 6.4.3. EGFR inhibitors
 - 6.4.4. ALK inhibitors
 - 6.4.5. ROSI inhibitors
 - 6.4.6. Others
- 6.5. Immunotherapy
 - 6.5.1. Pembrolizumab
 - 6.5.2. Durvalumab
 - 6.5.3. Nivolumab
 - 6.5.4. Atezolizumab
 - 6.5.5. Others

7. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION

- 7.1. Introduction
 - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
 - 7.1.2. Market Attractiveness Index, By Route of Administration
- 7.2. Oral*
 - 7.2.1. Introduction
 - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Intravenous

8. GLOBAL LUNG CANCER THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL

- 8.1. Introduction
 - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
 - 8.1.2. Market Attractiveness Index, By Distribution Channel
- 8.2. Hospital Pharmacies*
 - 8.2.1. Introduction

- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Retail Pharmacies
- 8.4. Online Pharmacies

9. GLOBAL LUNG CANCER THERAPEUTICS MARKET REGIONAL MARKET ANALYSIS AND GROWTH OPPORTUNITIES

9.1. Introduction

- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region

9.2. North America

- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.2.7.1. U.S.
 - 9.2.7.2. Canada
 - 9.2.7.3. Mexico

9.3. Europe

- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 9.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
 - 9.3.7.1. Germany
 - 9.3.7.2. U.K.
 - 9.3.7.3. France
 - 9.3.7.4. Spain
 - 9.3.7.5. Italy
 - 9.3.7.6. Rest of Europe

9.4. South America

- 9.4.1. Introduction

9.4.2. Key Region-Specific Dynamics

9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.4.7.1. Brazil

9.4.7.2. Argentina

9.4.7.3. Rest of South America

9.5. Asia-Pacific

9.5.1. Introduction

9.5.2. Key Region-Specific Dynamics

9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

9.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

9.5.7.1. China

9.5.7.2. India

9.5.7.3. Japan

9.5.7.4. South Korea

9.5.7.5. Rest of Asia-Pacific

9.6. Middle East and Africa

9.6.1. Introduction

9.6.2. Key Region-Specific Dynamics

9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type

9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type

9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of

Administration

9.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. COMPETITIVE LANDSCAPE AND MARKET POSITIONING

10.1. Competitive Overview and Key Market Players

10.2. Market Share Analysis and Positioning Matrix

10.3. Strategic Partnerships, Mergers & Acquisitions

10.4. Key Developments in Product Portfolios and Innovations

10.5. Company Benchmarking

11. COMPANY PROFILES

11.1. Key Players

11.2. Pfizer*

11.2.1. Company Overview

11.2.2. Product Portfolio

11.2.2.1. Product Description

11.2.2.2. Product Key Performance Indicators (KPIs)

11.2.2.3. Historic and Forecasted Product Sales

11.2.2.4. Product Sales Volume

11.2.3. Financial Overview

11.2.3.1. Company Revenue

11.2.3.2. Geographical Revenue Shares

11.2.3.3. Revenue Forecasts

11.2.4. Key Developments

11.2.4.1. Mergers & Acquisitions

11.2.4.2. Key Product Development Activities

11.2.4.3. Regulatory Approvals, etc.

11.2.5. SWOT Analysis

11.3. Merck & Co

11.4. Amgen Inc.

11.5. AstraZeneca

11.6. Boehringer Ingelheim

11.7. Bristol-Myers Squibb Company

11.8. Novartis AG

11.9. Eli Lilly and Company

11.10. Hoffmann-La Roche

11.11. AbbVie, Inc (LIST NOT EXHAUSTIVE)

12. ASSUMPTIONS AND RESEARCH METHODOLOGY

12.1. Data Collection Methods

12.2. Data Triangulation

12.3. Forecasting Techniques

12.4. Data Verification and Validation

13. APPENDIX

13.1. About Us and Services

13.2. Contact Us

I would like to order

Product name: Lung Cancer Therapeutics Market - 2023-2033

Product link: <https://marketpublishers.com/r/L00859AAFED7EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L00859AAFED7EN.html>